Quarter 2, December 2021 – February 2022
· Net revenue was 302 (0) tkr.
·EBITDA was -3 382 (-920) tkr.
· Operating cash flow was -739 (5 265) tkr.

Interim period, September 2021 – February 2022
· Net revenue was 302 (0) tkr.
· EBITDA was -6 935 (-1 112) tkr.
· Operating cash flow was -5 483 (5 216) tkr.
· Cash position in the end of period was 44 194 (686) tkr.
· Licensed products in the end of period were 27.
· Products with marketing authorization in the end of the period were 2.

Significant events during the quarter
· Enlargement of the oncology portfolio with the addition of Lapatinib.
· Agreement on an exclusive license to commercialize its own brand of Teduglutide 5mg pre-filled syringe in the Nordics.
· Completed capital raise of 50 mkr, pre capital raising costs, and listing on Nasdaq First North Growth Market.
· Ticagrelor Newbury approved by the Norwegian Health Authorities.
· Received international export order on approx. 3,4 mkr.
· Commercialization of Icatibant Newbury in Sweden and Norway.

Significant events after the end of the quarter
· Lenalidomide Newbury approved by the Swedish Health Authorities.
· Sunitinib Newbury approved by the Danish Health Authorities.

A word from the CEO
It has been another strong Quarter with significant milestones. I am proud of the achievements during this Quarter which fully align with expectations and our strategic road map.

First product has been launched
The first product has been launched in Scandinavia and we are able to record the first sales in Norway this Quarter. The sales opportunity arose from living our values of being curious and having a deep knowledge of the markets which gave us a window to sell Icatibant Newbury before the competitors in Norway. The sales recorded this period is covering the last month of the Quarter.

Another great milestone was the announcement of an export order valued at 3,4 mkr to be delivered in Q3 or Q4. 

Marketing authorizations have been granted for several products and markets
During the Quarter we received the registration of Ticagrelor Newbury in Norway and additional new registrations have been obtained in Q3 with Lenalidomide and Sunitinib receiving approval.

Pipeline is growing
Two new important licensing deals were entered during this Quarter. The two products are closely link to our strategic focus within oncology and rare diseases.
Lapatinib was in-licensed as a supplement to our oncology portfolio – and Teduglutide as part of our rare disease category. 
Teduglutide is a medicine for treating short bowel syndrome (or short gut) in adults. Due to the low number of patients with the condition, the disease is considered rare – and we see a huge potential for Teduglutide. We will work closely with the different stakeholders in our markets to make this medicine available for the patients in the coming years.

Executing the strategy road map
The organization has been expanded with a Head of Regulatory to oversee the many products having been filed with health authorities. This will support our ever-growing number of registrations across the Nordics.
Finally, a major milestone was achieved by ringing the Nasdaq bell on February the 4th where we were listed at Nasdaq First North Growth Markets, Stockholm. A strategic milestone which will enable the future growth of Newbury Pharmaceuticals and allow us to continue executing our strategic road map based on the completed capital raise of 50 mkr, pre capital raising costs.

The results in this Quarter demonstrate the focus on scaling the company for future launches and identifying new license opportunities as well as ongoing regulatory filings of our portfolio. All together we are making strong progress and are well prepared for further developing the company.